A share price of Editas Medicine Inc [EDIT] is currently trading at $2.10, up 8.81%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EDIT shares have gain 15.38% over the last week, with a monthly amount glided 44.83%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Editas Medicine Inc [NASDAQ: EDIT] stock has seen the most recent analyst activity on April 28, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $3. Previously, JP Morgan downgraded its rating to Underweight on December 16, 2024. On December 13, 2024, downgrade downgraded it’s rating to Hold. Stifel downgraded its rating to a Hold and decreased its price target to $3 on December 13, 2024. Chardan Capital Markets downgraded its rating to a Neutral. Wells Fargo downgraded its rating to Equal Weight for this stock on December 11, 2024, and downed its price target to $4. In a note dated November 25, 2024, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $13 to $1.
Editas Medicine Inc experienced fluctuations in its stock price throughout the past year between $0.91 and $6.22. Currently, Wall Street analysts expect the stock to reach $12.85 within the next 12 months. Editas Medicine Inc [NASDAQ: EDIT] shares were valued at $2.10 at the most recent close of the market. An investor can expect a potential return of 511.9% based on the average EDIT price forecast.
Analyzing the EDIT fundamentals
Trailing Twelve Months sales for Editas Medicine Inc [NASDAQ:EDIT] were 35.84M which represents 310.40% growth. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -5.91%, Pretax Profit Margin comes in at -8.06%, and Net Profit Margin reading is -8.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.95, Equity is -1.66 and Total Capital is -0.97. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.5.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Editas Medicine Inc [NASDAQ:EDIT] is 3.08. Further, the Quick Ratio stands at 3.08, while the Cash Ratio is 1.9. Considering the valuation of this stock, the price to sales ratio is 4.91, the price to book ratio is 2.82.
Transactions by insiders
Recent insider trading involved Parison Amy, SVP, Chief Financial Officer, that happened on Jun 03 ’25 when 446.0 shares were sold. EVP, CHIEF SCIENTIFIC OFFICER, Burkly Linda completed a deal on Jun 03 ’25 to sell 726.0 shares. Meanwhile, CEO O’Neill Gilmore Neil sold 15192.0 shares on Jun 03 ’25.
